Mamta Kalra joined Immatics in April 2016 and is responsible for manufacturing process development and viral vector-related assay development for ACT programs.
Mamta has extensive experience in the field of basic and applied Immunology that started with her doctoral research in TB vaccine development. She transitioned from Infectious Disease to Cancer Immunology during her postdoctoral years initially studying immunomodulatory factors in HCV-related liver cancer followed by T-cell therapy of EBV-related cancers. She was instrumental in optimizing manufacturing process for virus-specific and CAR-T cells. Her work also included potency testing of products and immune-monitoring for multiple adoptive T-cell therapy trials. Upon joining Immatics as a Sr. Scientist, she led process development for ACTengine program.
Mamta Kalra holds a PhD in Immunology from India and a postdoctoral training in adoptive T-cell therapy from Center for Cell and Gene Therapy at Baylor College of Medicine.